Therapeutic | Enfortumab |
Target | PVRL4 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS |
Light Chain | DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | Agensys, Seattle Genetics |
Conditions Approved | na |
Conditions Active | Urogenital cancer |
Conditions Discontinued | na |
Notes |